Efficacy of Multigrain Supplementation in Type II Diabetes Mellitus
Launched by UNIVERSITI SAINS MALAYSIA · Oct 20, 2020
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
Type II DM is a highly prevalent and heterogeneous condition. New treatment modalities to complement existing interventions are therefore of great interest, including dietary interventions for primary prevention or as a possible therapeutic option that may confer benefits beyond currently recommended conventional therapies. Hence, the present work aims to evaluate the efficacy of instant multigrain supplementation on the glycemic status, cardiometabolic implications, oxidative stress and nutritional status in Type II DM patients, as compare to standardized medication regimen.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Inclusion criteria for the clinical trial are:
- • Clinical diagnosis with Type II DM for at least 6 months' duration without clinically manifest complications (retinopathy, diabetic nephropathy, vascular diseases, foot ulcer - as diagnosed by the physician/recorded in database)
- • Male or female
- • Pharmacological treatment with metformin or insulin, or a combination of metformin and glibenclamide.
- • Chronological age: 18 years and above
- • Metabolically stable (current laboratory results for A1C 6.0-8.5%; or fasting plasma glucose 6.4-8.5 mmol/l)
- • Not taking antioxidant/anti-inflammatory supplements (Example of antioxidant: vitamin C, vitamin E, grape seed extract, garlic capsule, ginkgo biloba) (Example of anti-inflammatory supplement: fish oil, curcumin extract, ginger extract, spirulina)
- Exclusion Criteria:
- • Having liver (chronic liver failure, cirrhosis, all types of hepatitis), kidney (chronic kidney disease, haemodialysis) or haematological (anaemia, thalassemia, haemophilia) disorders
- • Active gastric/duodenal ulcer
- • Psychiatric disease/mental retardation (bipolar disorder, depression, schizophrenia)
- • Cancer (all types), and endocrine disorders (Cushing's disease, gigantism and hyperthyroidism).
- • Alcohol and drug abuse (self-mentioned or as recorded in the medical card)
- • Gestational Diabetes Mellitus
- • Pregnancy/lactation
- • Hormone replacement therapy (for at least 3 months prior to entering the study)
- • Herbal remedies (any parts from the plants such as flowers, rhizome, seeds, roots, leaves, fruits, stems)
- • Use of steroids, chemotherapy, immunosuppressant or radiotherapy.
- • Vegetarian patient (pure vegan)
- • Gluten intolerance
- • Participations currently under another supplementary program
About Universiti Sains Malaysia
Universiti Sains Malaysia (USM) is a leading research university in Malaysia, renowned for its commitment to advancing scientific knowledge and innovation in the healthcare sector. As a clinical trial sponsor, USM leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous research aimed at improving patient outcomes and addressing pressing health challenges. The university fosters collaboration among researchers, medical professionals, and industry partners, ensuring that its clinical trials are conducted with the highest ethical standards and scientific integrity. Through its dedication to excellence in research and education, USM plays a pivotal role in shaping the future of healthcare both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kepala Batas, Pulau Pinang, Malaysia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials